FDA: Mifepristone review won't be done until March
The Food and Drug Administration (FDA) won’t publish its safety review of the abortion drug mifepristone until March, it disclosed in a Wednesday court filing, adding that it won’t impose any new restrictions on the pill before that point. The revelations are likely to further anger anti-abortion activists, who have been losing patience with the...
Read it at The Hill See this on the map
What might happen next? AI-generated
These scenarios are written by an AI language model from the headline and summary above. They are not predictions from the newsroom, and they are not evidence of anything. Every one is given a deadline and checked against later coverage, and the score is published on the ledger — including the ones that miss.
ForecastGeo shows the headline and summary published by the newsroom and places the story on a map. The full article lives at the source.